Terumo : IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2021

August 4, 2021

Consolidated Financial Results

for the First Quarter Ended June 30, 2021

Terumo Corporation〔IFRS〕

Company name:	TERUMO CORPORATION
Listing:	Tokyo Stock Exchange
Securities code:	4543
URL:	https://www.terumo.com/
Representative:	Shinjiro Sato, President and CEO
Inquiries:	Kenichi Hata, General Manager, Investor Relations Dept.
Telephone:	[phone]

Scheduled date to file quarterly securities report:	August 6, 2021
Scheduled date to commence dividend payments:	－
Preparation of supplementary material on quarterly financial results: Yes
Holding of quarterly financial results briefing:	Yes (for Securities analysts, Institutional
	investors)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2021 (from April 1, 2021 to June 30, 2021)

(1) Consolidated operating results (cumulative)						(Percentages indicate year-on-year changes.)
														Profit for the	Profit attributable	Total
			Revenue	Operating profit	Profit before tax	comprehensive
			period	to owners of the
														income
																	parent
	Three months	Millions of	%	Millions of	%	Millions of		%	Millions of	%	Millions of	%	Millions of		%
	ended		yen		yen	yen		yen		yen	yen
	June 30, 2021	171,716	30.8	36,233	100.5	36,020		101.4	27,895	99.7	27,895	99.2	28,592		186.0
	June 30, 2020	131,298	(13.9)	18,073	(38.0)	17,885		(38.0)	13,971	(38.6)	14,002	(38.6)	9,997		267.9
			Basic earnings			Diluted earnings
			per share				per share
	Three months				Yen					Yen
	ended
	June 30, 2021				36.90				36.87
	June 30, 2020				18.57				18.50
Notes : Adjusted operating profit	June 2021: 40,203 million yen	June 2020: 21,685 million yen
(2) Consolidated financial position
														Equity attributable to		Ratio of equity
			Total assets		Total equity					attributable to owners of
								owners of parent
														parent to total assets
	As of			Millions of yen			Millions of yen			Millions of yen			%
	June 30, 2021			1,339,556			874,004			874,004			65.2
	March 31, 2021			1,351,192			856,662			856,662			63.4

－ 1 －

2. Cash dividends

		Annual dividends per share
	First quarter-end	Second quarter-end		Third quarter-end		Fiscal year-end	Total
	Yen	Yen		Yen		Yen	Yen
Fiscal year ended	－	14.00		－		15.00	29.00
March 31, 2021
Fiscal year ending	－
March 31, 2022
Fiscal year ending
March 31, 2022		15.00		－		15.00	30.00
(Forecast)

Note: Revision from the dividend forecast, which is published in the most recent : None

3. Consolidated Forecast for the Fiscal Year Ending March, 2022 (From April 1, 2021 to March 31, 2022) (Percentages indicate year-on-year changes.)

				Adjusted operating			Profit for the year
	Revenue		Operating profit	attributable to owners	Earnings per share
		profit
							of the parent
Fiscal Year ending	Millions of yen		%	Millions of yen	%	Millions of yen	%	Millions of yen		%	Yen
March, 2022	685,000		11.6	137,000	18.2	120,000	22.0	92,000		19.1	121.69

Notes: 1) Revision of forecast for fiscal year ending March, 2022 : Yes

1. Regarding the forecast for cumulative consolidated earnings for the fiscal year, please refer to the August 4th, 2021 press release "Terumo Revises its Full-Year Financial Guidance for FY2021".
2. Earnings per share is calculated by taking into consideration effects of the conversion of convertible bonds in the three months.

• Assumed exchange rate for fiscal year ending March, 2022: USD1=JPY108, EUR1=JPY129

－ 2 －

[Terumo Corporation] Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022

*Notes

(1) Changes in significant subsidiaries during the current quarterly consolidated cumulative period (changes in specified subsidiaries resulting in changes in the scope of consolidation): None

New － Company (Company Name) －, Excluded － Company (Company Name) －

1. Changes in accounting policies and changes in accounting estimates

1. Changes in accounting policies required by IFRS: None
2. Changes in accounting policies other than (i): None
3. Changes in accounting estimates: None

1. Number of shares outstanding (common stock)

1. Number of shares outstanding at the end of the period (including treasury shares)
2. Treasury shares at the end of the period
3. Average number of shares during the period (cumulative quarterly)

As of June 30, 2021	759,521,040 shares	As of March 31, 2021	759,521,040 shares
As of June 30,	2021	3,475,006 shares	As of March 31, 2021	3,508,047 shares
Three	months	ended	756,029,574 shares	Three	months ended	754,022,525 shares
June	30, 2021		June	30, 2020

*Quarterly financial statements are not subject to quarterly reviews by certified accountants or audit firms.

*Explanation on appropriate use of financial results forecasts and other special notes

1. Forward-lookingstatements, including earnings forecasts, contained in these disclosure materials are based on currently available information and assumptions believed to be reasonable by management. This is not a promise or guarantee by Terumo that it will achieve these goals. In addition, actual results may differ significantly due to several factors. For the assumptions that are the premise of the earnings forecast and the precautions for using the earnings forecast, refer to [Attachment], page 8, "1. Overview of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022 (3) Forecasts, including the Consolidated Financial Results for the Fiscal Year Ending March 31, 2022".
2. Adjusted operating profit factors out amortization expense for intangible assets obtained during acquisitions and one-off income and expenses from operating profit. In addition, adjusted operating profit is consistent with segment profit. We are disclosing adjusted operating profit as we are using it as a performance indicator.

－ 3 －

[Terumo Corporation] Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022
 Table of contents of attached materials
1. Overview of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022...........................	5
(1)	Overview of Consolidated Business Results......................................................................................................	5
(2)	Overview of Consolidated Statement of Financial Position ..............................................................................	8
(3)	Forecasts, including the Consolidated Financial Results for the Fiscal Year Ending March 31, 2022 ..............	8
2. Condensed Consolidated Financial Statements ......................................................................................................	9
(1)	Condensed Consolidated Statement of Financial Position.................................................................................	9
(2)	Condensed Consolidated Statement of Profit or Loss and Condensed Consolidated Statement of
	Comprehensive Income ...............................................................................................................................	11
(3)	Condensed Consolidated Statements of Changes in Equity.............................................................................	13
(4)	Notes Pertaining to Condensed Consolidated Financial Statements ................................................................	13
(i) Going Concern Assumption .........................................................................................................................	13
(ii) Segment information ..................................................................................................................................	14

－ 4 －

[Terumo Corporation] Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022

1. Overview of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022

(1) Overview of Consolidated Business Results

In the first quarter of the current fiscal year (from April 1, 2021 to June 30, 2021), the healthcare market experienced a recovery in medical demand especially in North America and Europe with the spread of the COVID-19 vaccination. There was increase in exams, diagnostics, hospitalizations, and elective procedures which had been postponed across various clinical departments as the impacts of the COVID-19 pandemic begun in the previous fiscal year largely eased. The Group's sales trended strongly owing to this recovery in its principal markets.

Financial results for the first quarter are as follows:

				(Millions of yen)
	For the three	For the three		Growth
		excluding impact
	months ended	months ended	Growth (%)
	of FX
	June 30, 2020	June 30, 2021
		translations (%)
Revenue	131,298	171,716	30.8	25.1
Gross profit	68,873	94,259	36.9	30.3
Adjusted operating profit	21,685	40,203	85.4	72.7
Operating profit	18,073	36,233	100.5	85.4
Profit before tax	17,885	36,020	101.4	－
Profit for the period	13,971	27,895	99.7	－
Profit for the period
attributable to owners of the	14,002	27,895	99.2	－
parent

Sales revenue by Geographic areas for the first quarter is as follows:

				(Millions of yen)
	For the three	For the three		Growth
		excluding impact
Geographic areas	months ended	months ended	Growth (%)
of FX
	June 30, 2020	June 30, 2021
		translations (%)
Japan	44,334	49,175	10.9	10.9
Europe	25,464	34,501	35.5	21.5
Americas	36,288	54,397	49.9	46.3
Asia and others	25,211	33,642	33.4	23.2
Overseas total	86,963	122,541	40.9	32.4
Total	131,298	171,716	30.8	25.1

－ 5 －